Extended Data Fig. 6: Additional correlations between autoantibodies targeting immune-cell surface proteins.
From: Diverse functional autoantibodies in patients with COVID-19
a, Average anti-SARS-CoV-2 RBD IgM reactivity as measured by ELISA in patients stratified by COVID-19 disease severity and REAP reactivity against B-cell-displayed proteins (as defined in Fig. 2e). b, Average percentage among total monocytes of classical monocytes, intermediate monocytes and nonclassical monocytes in patients stratified by COVID-19 disease severity and REAP reactivity against proteins preferentially displayed on classical and intermediate monocytes (as defined in Fig. 2f). c, Average per cent CD8+ T cells, natural killer T (NKT) cells and natural killer cells among peripheral leukocytes in patients stratified by COVID-19 disease severity and REAP reactivity against CD3ε. d, Average CD4+ T cell-to-natural killer cell ratio, CD8+ T cell-to-natural killer cell ratio and natural killer T cell-to-natural killer cell ratio among peripheral leukocytes in patients stratified by COVID-19 disease severity and REAP reactivity against CD3ε. e, Representative flow plot of T cells (CD3+), natural killer cells (CD56+) and natural killer T cells (CD3+CD56+) for c, d. f, Average per cent B cells, natural killer cells, activated CD4+ T cells and activated CD8+ T cells among peripheral leukocytes in patients stratified by COVID-19 disease severity and REAP reactivity against CD38. g, Representative flow plot of B cells (CD19+HLA-DR+) for f. h, Representative flow plot of activated CD8+ T cells (CD38+HLA-DR+) for f. Significance in a was determined using a two-sided Wilcoxon rank-sum test. All n values in this figure indicate samples from unique patients. All box plots are presented with the median, first and third quartile, whiskers (minimum and maximum values within the first and third quartiles ± 1.5× the interquartile range), and individual data points indicated.
